Are hypomethylating agents replacing induction-type chemotherapy before allogeneic stem cell transplantation in patients with myelodysplastic syndrome?

Biology of Blood and Marrow Transplantation

Volumn 20, Issue 12, 2014, Pages 1885-1890

  Yakoub Agha, Ibrahim ^a,b   Deeg, Joachim ^c,d  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE LILLE   (France)

^c Fred Hutchinson Cancer Research Center   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Allogeneic stem cell transplantation; Debulking treatment; Hypomethylating agents; Induction chemotherapy; Myelodysplastic syndrome; Up front transplantation

Indexed keywords

DNA METHYLTRANSFERASE INHIBITOR; HYPOMETHYLATING AGENT; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

ALGORITHM; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; GRAFT VERSUS LEUKEMIA EFFECT; HIGH RISK POPULATION; HUMAN; INCIDENCE; INDUCTION CHEMOTHERAPY; MYELODYSPLASTIC SYNDROME; OUTCOME ASSESSMENT; RECURRENCE FREE SURVIVAL; REMISSION; REVIEW; ALLOGRAFT; KARYOTYPE; MYELODYSPLASTIC SYNDROMES; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; STEM CELL TRANSPLANTATION;

ALLOGRAFTS; ANTINEOPLASTIC AGENTS; HUMANS; INDUCTION CHEMOTHERAPY; KARYOTYPE; MYELODYSPLASTIC SYNDROMES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; STEM CELL TRANSPLANTATION;

EID: 84912522092     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2014.06.023     Document Type: Review

References (48)

1. Bejar R., Stevenson K., Abdel-Wahab O., et al. Clinical effect of point mutations in myelodysplastic syndromes. NEngl J Med 2011, 364:2496-2506.
2. Delhommeau F., Dupont S., Della Valle V., et al. Mutation in TET2 in myeloid cancers. NEngl J Med 2009, 360:2289-2301.
3. Damm F., Itzykson R., Kosmider O., et al. SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias. Leukemia 2013, 27:1401-1403.
4. Thol F., Kolking B., Hollink I.H., et al. Analysis of NUP98/NSD1 translocations in adult AML and MDS patients. Leukemia 2013, 27:750-754.
5. Itzykson R., Kosmider O., Cluzeau T., et al. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia 2011, 25:1147-1152.
6. Itzykson R., Thepot S., Eclache V., et al. Prognostic significance of monosomal karyotype in higher risk myelodysplastic syndrome treated with azacitidine. Leukemia 2011, 25:1207-1209.
7. Ades L., Fenaux P. Immunomodulating drugs in myelodysplastic syndromes. Hematol Am Soc Hematol Educ Progr 2011, 2011:556-560.
8. Deeg H.J., Gotlib J., Beckham C., et al. Soluble TNF receptor fusion protein (etanercept) for the treatment of myelodysplastic syndrome: a pilot study. Leukemia 2002, 16:162-164.
9. Fenaux P., Mufti G.J., Hellstrom-Lindberg E., et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009, 10:223-232.
10. Lubbert M., Suciu S., Baila L., et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. JClin Oncol 2011, 29:1987-1996.
11. de Witte T., Hagemeijer A., Suciu S., et al. Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup Trial. Haematologica 2010, 95:1754-1761.
12. Deeg H.J., Guardiola P. Allogeneic hemopoietic stem cell transplantation in patients with myelodysplastic syndrome or myelofibrosis. Int J Hematol 2002, 76(Suppl 2):29-34.
13. Yakoub-Agha I., de La Salmoniere P., Ribaud P., et al. Allogeneic bone marrow transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia: a long-term study of 70 patients-report of the French Society of Bone Marrow Transplantation. JClin Oncol 2000, 18:963-971.
14. de Witte T., Brand R., van Biezen A., et al. Allogeneic stem cell transplantation for patients with refractory anaemia with matched related and unrelated donors: delay of the transplant is associated with inferior survival. Br J Haematol 2009, 146:627-636.
15. Fenaux P., Mufti G.J., Hellstrom-Lindberg E., et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. JClin Oncol 2010, 28:562-569.
16. Warlick E.D., O'Donnell P.V., Borowitz M., et al. Myeloablative allogeneic bone marrow transplant using T cell depleted allografts followed by post-transplant GM-CSF in high-risk myelodysplastic syndromes. Leuk Res 2008, 32:1439-1447.
17. Scott B.L., Estey E. Management of myelodysplastic syndromes: 2008 update. Oncology 2008, 22:1344-1352.
18. Fenaux P., Morel P., Rose C., et al. Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy. Br J Haematol 1991, 77:497-501.
19. Itzykson R., Thepot S., Quesnel B., et al. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood 2012, 117:403-411.
20. Della Porta M.G., Alessandrino E.P., Bacigalupo A., et al. Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R. Blood 2014, 123:2333-2342.
21. Rollison D.E., Howlader N., Smith M.T., et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood 2008, 112:45-52.
22. De Roos A.J., Deeg H.J., Onstad L., et al. Incidence of myelodysplastic syndromes within a nonprofit healthcare system in western Washington state, 2005-2006. Am J Hematol 2010, 85:765-770.
23. Atallah E., Cortes J., O'Brien S., et al. Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia. Blood 2007, 110:3547-3551.
24. Estey E., de Lima M., Tibes R., et al. Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Blood 2007, 109:1395-1400.
25. Scott B.L., Storer B., Loken M.R., et al. Pretransplantation induction chemotherapy and posttransplantation relapse in patients with advanced myelodysplastic syndrome. Biol Blood Marrow Transplant 2005, 11:65-73.
26. Field T., Perkins J., Huang Y., et al. 5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2010, 45:255-260.
27. Damaj G., Duhamel A., Robin M., et al. Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the Societe Francaise de Greffe de Moelle et de Therapie-Cellulaire and the Groupe-Francophone des Myelodysplasies. JClin Oncol 2012, 30:4533-4540.
28. Gerds A.T., Gooley T.A., Estey E.H., et al. Pretransplantation therapy with azacitidine vs induction chemotherapy and posttransplantation outcome in patients with MDS. Biol Blood Marrow Transplant 2012, 18:1211-1218.
29. Vigil C.E., Martin-Santos T., Garcia-Manero G. Safety and efficacy of azacitidine in myelodysplastic syndromes. Drug Des Devel Ther 2010, 4:221-229.
30. Merkel D., Filanovsky K., Gafter-Gvili A., et al. Predicting infections in high-risk patients with myelodysplastic syndrome/acute myeloid leukemia treated with azacitidine: a retrospective multicenter study. Am J Hematol 2013, 88:130-134.
31. Robin M., Porcher R., Ades L., et al. Outcome of patients with IPSS intermediate (int) or high risk myelodysplastic syndrome (MDS) according to donor availability: a multicenter prospective non interventional study for the SFGM-TC and GFM. Blood 2013, 122:301.
32. Prebet T., Gore S.D., Esterni B., et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. JClin Oncol 2011, 29:3322-3327.
33. Damaj G., Mohty M., Robin M., et al. Up-front allogeneic stem cell transplantation following reduced intensity/nonmyeloablative for patients with myelodysplastic syndrome. A study by the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC). Biol Blood Marrow Transplant 2014.
34. Goodyear O.C., Dennis M., Jilani N.Y., et al. Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML). Blood 2012, 119:3361-3369.
35. Martino M., Fedele R., Moscato T., Ronco F. Optimizing outcomes following allogeneic hematopoietic progenitor cell transplantation in AML: the role of hypomethylating agents. Curr Cancer Drug Targets 2013, 13:661-669.
36. Cazzola M., Della Porta M.G., Malcovati L. The genetic basis of myelodysplasia and its clinical relevance. Blood 2013, 122:4021-4034.
37. Cluzeau T., Moreilhon C., Mounier N., et al. Total genomic alteration as measured by SNP-array-based molecular karyotyping is predictive of overall survival in a cohort of MDS or AML patients treated with azacitidine. Blood Cancer J 2013, 3:e155.
38. Haferlach T., Nagata Y., Grossmann V., et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 2013, 28:241-247.
39. Yakoub-Agha I., Mesnil F., Kuentz M., et al. Allogeneic marrow stem-cell transplantation from human leukocyte antigen-identical siblings versus human leukocyte antigen-allelic-matched unrelated donors (10/10) in patients with standard-risk hematologic malignancy: a prospective study from the French Society of Bone Marrow Transplantation and Cell Therapy. JClin Oncol 2006, 24:5695-5702.
40. Lee S.J., Klein J., Haagenson M., et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 2007, 110:4576-4583.
41. Ooi J., Iseki T., Takahashi S., et al. Unrelated cord blood transplantation for adult patients with advanced myelodysplastic syndrome. Blood 2003, 101:4711-4713.
42. Kim E.H., Ikegame K., Kawakami M., et al. Unmanipulated reduced-intensity stem cell transplantation from a haploidentical donor mismatched at 3 HLA antigens to a patient with leukemic transformation of myelodysplastic syndrome: successful second transplantation after graft rejection. Int J Hematol 2004, 80:449-452.
43. Lee K.H., Lee J.H., Kim D.Y., et al. Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome. Blood 2011, 118:2609-2617.
44. Guardiola P., Runde V., Bacigalupo A., et al. Retrospective comparison of bone marrow and granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for allogeneic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes. Blood 2002, 99:4370-4378.
45. Anasetti C., Logan B.R., Lee S.J., et al. Peripheral-blood stem cells versus bone marrow from unrelated donors. NEngl J Med 2012, 367:1487-1496.
46. Sorror M.L. How I assess comorbidities before hematopoietic cell transplantation. Blood 2013, 121:2854-2863.
47. Parimon T., Au D.H., Martin P.J., Chien J.W. Arisk score for mortality after allogeneic hematopoietic cell transplantation. Ann Intern Med 2006, 144:407-414.
48. Deeg H.J., Sandmaier B.M. Who is fit for allogeneic transplantation?. Blood 2010, 116:4762-4770.